statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

(ALNY) - Analyzing Alnylam Pharmaceuticals's Short Interest

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the publication of its 2023 Corporate Responsibility Report. The company continues to take...

Alnylam Issues 2023 Corporate Responsibility Report

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2024 and reviewed recent...

Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity

Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets...

Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia

How Is The Market Feeling About Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2024 on Thursday, May...

Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results

The latest findings from Alnylam Pharmaceuticals' KARDIA-2 Phase 2 study are on zilebesiran's efficacy and safety in treating hypertension. Results show significant reductions in systolic blood...

Analysts Express Confidence in Alnylam's Hypertension Drug Despite Mixed Trial Data

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced positive results from the KARDIA-2 Phase 2 study evaluating the efficacy and safety of a single...

Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension

SteelPeak Wealth LLC lowered its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 37.4% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by SteelPeak Wealth LLC

BMO Capital Markets reissued their outperform rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY - Free Report) in a report published on Wednesday morning, Benzinga reports. The brokerage...

Alnylam Pharmaceuticals (NASDAQ:ALNY) Earns Outperform Rating from BMO Capital Markets

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Watchers	4,023
52-Wk Low	$141.98
52-Wk High	$218.88

Volume	195,501.00
52-Wk High	$218.88
52-Wk Low	$141.98

Period	Estimated	Reported	Surprise	Result
Q2'24	-$1.06	--	--	N/A
Q1'24	-$1.12	-$0.52	53.41%	BEAT
Q4'23	-$1.19	-$1.10	7.32%	BEAT
Q3'23	-$1.45	$1.15	179.55%	BEAT
Q2'23	-$1.51	-$2.21	-46.76%	MISSED

ALNY Alnylam Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals